Taken together, blocking the compensatory upregulation of other checkpoint inhibitors such as TIM3 and LAG3 after anti-PD1/PDL1 treatment could be an important pharmaceutical strategy to overcome primary and secondary resistance to PD1/PDL1 blockade in patients with advanced HCC in the future. Here, HAVCR2 is linked to hepatocellular carcinoma.